According to the latest research by InsightAce Analytic, the global Therapeutic Proteins and Oral Vaccines market is valued at US$ 219.89 Billion in 2021, and it is expected to grow with a CAGR of 7.08% during a forecast period of 2022-2030. Therapeutic proteins are genetically engineered proteins that have a wide range of treatment applications. Therapeutic proteins are mainly prepared for pharmaceutical use. Oral vaccines are biologically prepared products, which are used in treating or preventing various infectious diseases. The increasing number of pharmaceutical drug developments or innovations is expected to drive the growth of the therapeutic protein and oral vaccine market in the near future.
Major driving factors of the therapeutic proteins and oral vaccines market are the increasing need for therapeutic proteins and oral vaccines, high prevalence of cancer diseases, rising number of clinical trials, increasing investments by key players for the development of promising therapies. Furthermore, advanced medical technologies, growth in the population, and a growing number of health-conscious people are enhancing the growth of the therapeutic proteins and oral vaccines market. However, the high price of devices, complex procedures, lack of strict government laws are restraining the growth of this market.
The therapeutic proteins and oral vaccines market is segmented into Drug Class, Distribution Channels, Applications, and regions. The Drug Class segment is further bifurcated into Therapeutic Proteins and Oral Vaccines. Therapeutic Proteins are subdivided into Therapeutic Proteins, Growth Factors, Fusion Proteins, Monoclonal Antibodies, Hormones, Coagulation Factors, and Other Therapeutic Proteins. While, Oral Vaccines are subdivided into Live Attenuated Vaccine, Inactivated Vaccine, Recombinant Vaccine, and Other Oral Vaccines. In the coming future, therapeutic proteins will be in high scope due to their effective and fast results and rise in therapy innovations. By Distribution Channels, the market is segmented into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. Hospital Pharmacies will upscale the market of therapeutic proteins and oral vaccines over the forecast period. In terms of Applications, the market can be divided into Oncology, Hematology, Immunology, Endocrinology, Infectious Disease, Cardiovascular Disease, and Other Applications. Oncology and Infectious diseases are the fastest-growing segments of this market due to the increasing prevalence of cancer and infectious diseases. Based on the region, the therapeutic proteins and oral vaccines market is divided into North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa. North America followed by Europe holds the maximum share of this market due to increased research and development expenditure, presence of significant market players and fast adaption of advanced technologies.
Major key Players of therapeutic proteins and oral vaccines market are Abbott Laboratories, Amgen, Inc., Biogen, Inc., Eily, Lilly, and Company, F. Hoffmann-La Roche, Johnson and Johnson, Merck & Co., Novo Nordisk, Pfizer, Inc., Sanofi S.A., Serum Institute of India Pvt. Ltd., Emergent Biosolutions Inc., TransAlgae, MigVax Ltd, Lumen Bioscience, Inc., and Other Prominent Players.
